Hovilpri (pritelivir)

Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults

Also known as AIC316

Manufacturer: Asahi Kasei Therapeutics
Regulatory submission: NDA submitted February 2026 and approved October 2026
Launch: Anticipated before the end of 2026
Last updated: October 11, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

330 evidence topics · 94 sources

Current treatment options and standard of care208 evidence topics · 67 sources
Place in treatment, anticipated use, and care setting28 evidence topics · 21 sources
Heterogeneity of treatment effect31 evidence topics · 12 sources
Care management intervention strategies31 evidence topics · 21 sources
Other product development or post-marketing obligations required by the FDA6 evidence topics · 6 sources
Ongoing post-approval monitoring4 evidence topics · 2 sources
Expected outcomes of therapy22 evidence topics · 9 sources